aTyr Pharma (NASDAQ:ATYR) Issues Earnings Results

aTyr Pharma (NASDAQ:ATYR) released its quarterly earnings results on Thursday. The company reported ($7.43) earnings per share for the quarter, missing the consensus estimate of ($4.00) by ($3.43), FiscalAI reports.

aTyr Pharma Stock Performance

Shares of NASDAQ ATYR traded down $0.15 during mid-day trading on Thursday, reaching $6.03. 58,833 shares of the company were exchanged, compared to its average volume of 100,043. aTyr Pharma has a 52 week low of $4.07 and a 52 week high of $44.40. The company’s 50 day moving average price is $11.99 and its 200 day moving average price is $23.70.

Analysts Set New Price Targets

Several research analysts have recently commented on ATYR shares. Weiss Ratings lowered aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Wall Street Zen raised shares of aTyr Pharma to a “hold” rating in a research note on Saturday, October 31st. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, aTyr Pharma has a consensus rating of “Moderate Buy”.

About aTyr Pharma

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.